A Phase II Study Of The Weekly Administration Of Docetaxel In Combination With Ther Epidermal Growth Factor Receptor Inhibitor OSI-774 In Recurrent And/Or Metastatic Breast Cancer.

Trial Profile

A Phase II Study Of The Weekly Administration Of Docetaxel In Combination With Ther Epidermal Growth Factor Receptor Inhibitor OSI-774 In Recurrent And/Or Metastatic Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2016

At a glance

  • Drugs Docetaxel (Primary) ; Erlotinib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jun 2011 Planned end date changed from 1 Sep 2013 to 1 Apr 2015 as reported by ClinicalTrials.gov.
    • 13 Jan 2011 Planned end date (Mar 2007) added as reported by ClinicalTrials.gov.
    • 02 Mar 2010 Actual patient number (39) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top